# N. Costedoat‐Chalumeau

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/n-costedoat-chalumeau/

## Facts

| Field | Value |
| --- | --- |
| Citations | 28,335 |
| Field | Systemic Lupus Erythematosus Research |
| h-index | 83 |
| i10-index | 276 |
| Last Known Institution | Délégation Paris 5 |
| OpenAlex ID | https://openalex.org/A5062315921 |
| ORCID iD | https://orcid.org/0000-0002-1555-9021 |
| Works | 807 |

## Researcher papers

- [2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus](https://scholariq.org/papers/2019-european-league-against-rheumatism-american-college-of-rheumatology/)
- [2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus](https://scholariq.org/papers/2019-european-league-against-rheumatism-american-college-of-rheumatology-2/)
- [EULAR recommendations for the management of antiphospholipid syndrome in adults](https://scholariq.org/papers/eular-recommendations-for-the-management-of-antiphospholipid-syndrome-in-adults/)
- [The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation](https://scholariq.org/papers/the-eular-points-to-consider-for-use-of-antirheumatic-drugs-before-pregnancy-and/)
- [EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome](https://scholariq.org/papers/eular-recommendations-for-women-s-health-and-the-management-of-family-planning/)
- [Treat-to-target in systemic lupus erythematosus: recommendations from an international task force](https://scholariq.org/papers/treat-to-target-in-systemic-lupus-erythematosus-recommendations-from-an/)
- [Maternal Use of Hydroxychloroquine Is Associated With a Reduced Risk of Recurrent Anti-SSA/Ro-Antibody–Associated Cardiac Manifestations of Neonatal Lupus](https://scholariq.org/papers/maternal-use-of-hydroxychloroquine-is-associated-with-a-reduced-risk-of/)
- [The 2023 <scp>ACR</scp>/<scp>EULAR</scp> Antiphospholipid Syndrome Classification Criteria](https://scholariq.org/papers/the-2023-scp-acr-scp-scp-eular-scp-antiphospholipid-syndrome-classification/)
- [2023 ACR/EULAR antiphospholipid syndrome classification criteria](https://scholariq.org/papers/2023-acr-eular-antiphospholipid-syndrome-classification-criteria/)
- [2021 DORIS definition of remission in SLE: final recommendations from an international task force](https://scholariq.org/papers/2021-doris-definition-of-remission-in-sle-final-recommendations-from-an/)
- [A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS)](https://scholariq.org/papers/a-framework-for-remission-in-sle-consensus-findings-from-a-large-international/)
- [Long-term efficacy and safety of rituximab in IgG4-related disease: Data from a French nationwide study of thirty-three patients](https://scholariq.org/papers/long-term-efficacy-and-safety-of-rituximab-in-igg4-related-disease-data-from-a/)

## Researcher topics

- [Systemic Lupus Erythematosus Research](https://scholariq.org/topics/systemic-lupus-erythematosus-research/)
- [Pregnancy and Medication Impact](https://scholariq.org/topics/pregnancy-and-medication-impact/)
- [Renal Diseases and Glomerulopathies](https://scholariq.org/topics/renal-diseases-and-glomerulopathies/)
- [Systemic Sclerosis and Related Diseases](https://scholariq.org/topics/systemic-sclerosis-and-related-diseases/)
- [Drug-Induced Ocular Toxicity](https://scholariq.org/topics/drug-induced-ocular-toxicity/)

## Researcher university

- [Délégation Paris 5](https://scholariq.org/institutions/delegation-paris-5/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.